Court dismisses Verus suit against AZ

AstraZeneca has won dismissal of a lawsuit in which it was accused of backing out of a deal with Verus Pharmaceuticals to develop a children's asthma drug and instead aligning with competitor Map Pharmaceuticals. Verus had been seeking at least $280 million in compensatory damages and $1 billion in punitive damages. Verus claimed that once AstraZeneca entered a deal with Map, it sought to kill any competition by destroying Verus's ability to develop the drug on its own. Article | Report